Serina Therapeutics Inc./$SER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Ticker
$SER
Sector
Primary listing
AMEX
Employees
-
Headquarters
Website
SER Metrics
BasicAdvanced
$22m
-
-$1.91
0.10
-
Price and volume
Market cap
$22m
Beta
0.1
52-week high
$7.92
52-week low
$1.22
Average daily volume
6.5m
Financial strength
Current ratio
1.706
Quick ratio
0.858
Long term debt to equity
-8,491.892
Total debt to equity
-8,981.081
Interest coverage (TTM)
-112.78%
Profitability
EBITDA (TTM)
-23.949
Gross margin (TTM)
-10,019.23%
Net profit margin (TTM)
-14,755.38%
Operating margin (TTM)
-18,478.46%
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-219.58%
Return on equity (TTM)
-8,159.24%
Valuation
Price to revenue (TTM)
142.667
Price to book
-3.94
Price to tangible book (TTM)
-3.94
Price to free cash flow (TTM)
-1.03
Free cash flow yield (TTM)
-97.13%
Free cash flow per share (TTM)
-1.768
Growth
Revenue change (TTM)
132.14%
Earnings per share change (TTM)
25.99%
3-year revenue growth (CAGR)
-39.65%
3-year earnings per share growth (CAGR)
15.11%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Serina Therapeutics Inc. stock?
Serina Therapeutics Inc. (SER) has a market cap of $22M as of May 01, 2026.
What is the P/E ratio for Serina Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Serina Therapeutics Inc. (SER) stock is 0 as of May 01, 2026.
Does Serina Therapeutics Inc. stock pay dividends?
No, Serina Therapeutics Inc. (SER) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Serina Therapeutics Inc. dividend payment date?
Serina Therapeutics Inc. (SER) stock does not pay dividends to its shareholders.
What is the beta indicator for Serina Therapeutics Inc.?
Serina Therapeutics Inc. (SER) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.